While second-generation BTK inhibitors are clinically similar, the next major advance in combination therapy may come from the BCL2 inhibitor component. The newer agent sonrotoclax is potentially more potent and selective than venetoclax, which could lead to superior efficacy and tolerability in future regimens.

While pirtobrutinib works after covalent BTK inhibitors, no data shows covalent inhibitors work after pirtobrutinib failure. This uncertainty about future options makes clinicians cautious about using it as an initial therapy, especially for younger CLL patients who will need multiple treatments over their lifetime.

Non-covalent BTK inhibitors like pirtobrutinib are currently approved for use after covalent BTK inhibitors fail. Moving them to the frontline setting, as studied in BRUIN-313, disrupts the established treatment pathway and creates uncertainty for managing relapsed disease, as the standard 'next step' is removed.

Early data from the CLL 314 study shows a progression-free survival benefit for pirtobrutinib over ibrutinib in frontline CLL patients. This finding suggests a potential future shift where non-covalent BTK inhibitors could become the initial standard of care.

Despite a major trial using rituximab in its pirtobrutinib-venetoclax combination, experts note a strong clinical preference for obinutuzumab as the more effective anti-CD20 antibody in CLL. This suggests that in real-world practice, clinicians may substitute obinutuzumab, adapting the trial regimen for perceived superior efficacy.

The BRUIN-313 trial successfully compared pirtobrutinib to bendamustine-rituximab (BR). However, BR is no longer the frontline standard of care. This 'straw man' comparator makes it difficult to position pirtobrutinib against current preferred treatments like other BTK inhibitors or venetoclax regimens, limiting immediate clinical applicability.

Despite strong single-agent trial results, experts believe the field is shifting away from continuous monotherapy. The most significant future impact for pirtobrutinib will likely be as a backbone of fixed-duration combination therapies with drugs like venetoclax, aiming for deeper remissions without indefinite treatment.

While pirtobrutinib was already used off-label per NCCN guidelines, its official FDA approval provides a government-sanctioned alternative, forcing a direct decision between it and a venetoclax-based regimen for patients relapsing on a prior BTK inhibitor.

For high-risk CLL patients who progress after both covalent BTK inhibitors and venetoclax, pirtobrutinib is not just the next line of therapy. It is strategically used to achieve disease control, creating a window to prepare the patient for a more definitive and potentially curative CAR-T cell therapy.